首页>投融资
Cybin
上市后再融资
Cybin Inc.于2019年在加拿大安大略省成立。该公司在加拿大、美国、英国和爱尔兰开展业务。该公司专注于通过设计专利药物发现平台，创新药物输送系统，新型配方方法和精神健康障碍治疗方案，将迷幻药发展为治疗学。
基本信息
-
公司全称Cybin Inc
-
类型迷幻药物开发、研发商
-
产业领域生物/化学技术、药品研发/制造、化学药
-
公司人数15~50人
-
地址100 King Street West Suite 5600 Toronto Ontario Canada M5X 1C9
-
联系电话18884229246
-
邮箱info@cybin.com
-
成立时间2019-01-01
投融资
-
2024-03-19上市后再融资1.5亿美元Deep Track CapitalRA CapitalAvidity PartnersAcorn BioventuresAltium CapitalLogos Capital八方资本Rosalind AdvisorsSphera Global Healthcare Fund
-
2023-11-10上市后再融资3000万美元未透露
-
2023-08-01增发825万美元未透露
-
2021-08-05上市未透露未透露
-
2021-07-27增发未透露未透露
-
2021-02-04上市后再融资2726万美元未透露
-
2020-11-10上市未透露未透露
-
2020-10-30股权融资3576万美元Innovating Capital
- 加载更多
相关投融资企业
B轮
Confo Therapeutics is a spin-off company of VIB and Vrije Universiteit Brussel focused on drugs targeting G-protein coupled receptors using its proprietary CONFO technology platform.In May 2019, Confo Therapeutics raised EUR 30 million (US $33.4 million) in Series A financing.In June 2015, the company raised EUR 3 million (US $3.37 million) in the first institutional round of investment by a consortium led by Capricorn Health-Tech Fund with the participation of Qbic and SOFI. In February 2016, the company had secured EUR 6.7 million (US $7.47 million) in the first financing round
捐赠/众筹/授予
Confo Therapeutics is a spin-off company of VIB and Vrije Universiteit Brussel focused on drugs targeting G-protein coupled receptors using its proprietary CONFO technology platform.In May 2019, Confo Therapeutics raised EUR 30 million (US $33.4 million) in Series A financing.In June 2015, the company raised EUR 3 million (US $3.37 million) in the first institutional round of investment by a consortium led by Capricorn Health-Tech Fund with the participation of Qbic and SOFI. In February 2016, the company had secured EUR 6.7 million (US $7.47 million) in the first financing round
浙公网安备33011002015279
本网站未发布麻醉药品、精神药品、医疗用毒性药品、放射性药品、戒毒药品和医疗机构制剂的产品信息